Loading stock…

Medpace Holdings, Inc. (MEDP) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Medpace Holdings, Inc.

MEDPMarket cap $17BPrice $604.3

Country🇺🇸United States

SectorHealthcare

IndustryLife Sciences

Medpace runs clinical trials for biotech and pharma companies, guiding drugs from lab to FDA approval. It's the behind-the-scenes engine for hundreds of new therapies, and it turns a profit margin most CROs can only dream of.

In Bastion Portfolios?

52W Return+14%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+20%9

Revenue Forecast

Rev CAGR (1y)+13%7

Rev CAGR (3y)+10%7

Rev CAGR (5y)+9%7

Earnings Forecast

EPS Growth Y+1+18%8

EPS Growth Y+2+9%6

EPS Growth Y+3+11%7

Quality

Margins

EBIT Margin21%8

Net Income Margin18%7

Free Cash Flow Margin25%9

Debt

Net Debt/EBITDA-0.510

Efficiency

ROE162%10

ROA27%10

Earnings Stability1010

GEAR+VERY STRONG86

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)322

P/E Ratio (Forward 3y)282

P/BV38.91

EV Multiples

EV/EBITDA Fwd262

EV/EBIT Fwd272

Yield

Free Cash Flow Yield4.2%6

Dividend Yieldna–

Momentum

Short term

1 month return+2%9

3 month return+14%9

YTD return+8%6

Mid term

Price vs 52wHigh89%8

1 year return+14%6

Long term

3 year return+146%8

5 year return+220%9

Risk Shield

Price Risk

Beta1.04

Volatility46%3

Free Cash Flow

Free Cash Flow Margin25%9

Free Cash Flow Yield4.2%6

Quality

ROCE120%10

Earnings Stability1010

Net Debt/EBITDA-0.510

02Growth

Is it actually growing, and how fast?

MEDPMedpace Holdings

Revenue FY25$2.5B

GROWTH RATING↗

STRONG70 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+20%9

Revenue, next 1Y+13%7

Revenue, next 3Y, CAGR+10%7

Revenue, next 5Y, CAGR+9%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+18%8

EPS growth, FY27E+9%6

EPS growth, FY28E+11%7

GROWTH ASSESSMENT

STRENGTHS

It out-grows 70% of companies worldwide.

Revenue grew 20%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 10%/yr over the next 3 years, ahead of most of the market.7/10

The runway holds up: revenue is set to grow 9%/yr over five years.7/10

Earnings are set to grow in step with sales (EPS about 11%/yr vs revenue 10%/yr).

WATCH

Revenue grew 20%/yr over the last 3 years; forecasts see it cooling to 10%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG89 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+2%9

3-month return+14%9

YTD return+8%6

MID & LONG-TERM▾SCORE

% of 52-week high89%8

1-year return+14%6

3-year return+146%8

5-year return+220%9

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +146% over three years and +220% over five, ahead of 80% of the market.

It's up 14% over the past year, but 11% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+2%) and over three months (+14%).

WATCH

Returns sit at the market level so far this year (+8%).

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Medpace Holdings, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

MEDPMedpace Holdings

Revenue FY25$2.5B

GROWTH RATING↗

STRONG70 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+20%9

Revenue, next 1Y+13%7

Revenue, next 3Y, CAGR+10%7

Revenue, next 5Y, CAGR+9%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+18%8

EPS growth, FY27E+9%6

EPS growth, FY28E+11%7

GROWTH ASSESSMENT

STRENGTHS

It out-grows 70% of companies worldwide.

Revenue grew 20%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 10%/yr over the next 3 years, ahead of most of the market.7/10

The runway holds up: revenue is set to grow 9%/yr over five years.7/10

Earnings are set to grow in step with sales (EPS about 11%/yr vs revenue 10%/yr).

WATCH

Revenue grew 20%/yr over the last 3 years; forecasts see it cooling to 10%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG89 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+2%9

3-month return+14%9

YTD return+8%6

MID & LONG-TERM▾SCORE

% of 52-week high89%8

1-year return+14%6

3-year return+146%8

5-year return+220%9

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +146% over three years and +220% over five, ahead of 80% of the market.

It's up 14% over the past year, but 11% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+2%) and over three months (+14%).

WATCH

Returns sit at the market level so far this year (+8%).

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Medpace Holdings, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community